BSE filing, NSE: MOLBIO. Summary written from the filing by ALFA Finder's alert engine.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,286.00
- Market cap
- ₹14,820 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- Promoter holding
- 41.29%
- FII holding
- 1.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Price Movement Clarification
Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.
Molbio Diagnostics Other Announcement
Molbio Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides information on promoter and public shareholding structures.
Molbio Diagnostics Capital Structure Change
Kotak Mahindra Mutual Fund acquired 5,70,000 Molbio Diagnostics shares in the open market on 08 October 2026. Its stake crossed 5% to 5.4834%.
Molbio Diagnostics Other Announcement
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
- Execution
- 12 months
Molbio Diagnostics Board Meeting Outcome
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
- Execution
- Financial Year 2026-27
Molbio Diagnostics Capital Structure Change
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Other other announcement announcements
All →Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.
Man Infraconstruction Other Announcement
Man Infraconstruction filed a Reg 32 quarterly statement confirming no deviation in use of preferential-warrant proceeds. No deviation or variation arose for the quarter ended September 30, 2026.
Black Buck Other Announcement
BlackBuck's ICRA monitoring agency report for Q1 FY27 confirms IPO proceeds utilization remains in line with stated objects. No deviation was observed in the quarter.
Raama Finance Other Announcement
Raama Finance appointed M/s. Kumar Gaurav & Co. as statutory auditor for three months effective October 29, 2026. The routine appointment carries no financial impact.
Teja Engineering Industries Other Announcement
Teja Engineering Industries filed a non-applicability certificate for Reg 27(2) Corporate Governance for Q1 FY27. As an NSE Emerge-listed SME, the company is exempt from this periodic disclosure.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.